← Eichor
Condition: Homologous Recombination Deficiency Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Homologous Recombination Deficiency

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Phase 2 · 18 location(s) · VA Office of Research and Development · NCT04038502Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
Phase 1 · 2 location(s) · Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · NCT06666270Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Without Homologous Recombina
Phase N/A · 1 location(s) · Centre Hospitalier Universitaire de Nīmes · NCT06827353Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
Phase 1 · 1 location(s) · Varun Monga, MBBS · NCT06177171Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homo
Phase 1/Phase 2 · 19 location(s) · AstraZeneca · NCT07446855Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency
Phase 2/Phase 3 · 1 location(s) · Fudan University · NCT06095141Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 · 18 location(s) · MOMA Therapeutics · NCT06545942Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Phase 1 · 18 location(s) · Duke Street Bio Ltd · NCT06458712Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Phase 3 · 676 location(s) · NRG Oncology · NCT06580314PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficie
Phase 2/Phase 3 · 1 location(s) · N.N. Alexandrov National Cancer Centre · NCT07472140HRD Tests for Ovarian cancER
Phase 2 · 4 location(s) · Centre Francois Baclesse · NCT06152731Distribution of the Homologous Recombination-related (HRR) Genesmutationsand HRD in Breast Cancer
Phase N/A · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT05466786Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
Phase 1 · 8 location(s) · Senhwa Biosciences, Inc. · NCT04890613Exploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
Phase N/A · 1 location(s) · Geneplus-Beijing Co. Ltd. · NCT05965557Olaparib in Patients With HRD Malignant Mesothelioma
Phase 2 · 1 location(s) · University of Chicago · NCT04515836Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian
Phase 1 · 2 location(s) · University of Colorado, Denver · NCT06856499Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07033819EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Eisbach Bio GmbH · NCT06525298A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Phase 1/Phase 2 · 4 location(s) · AtlasMedx, Incorporated · NCT04503265Bipolar Androgen Therapy + Carboplatin in mCRPC
Phase 2 · 1 location(s) · St Vincent's Hospital, Sydney · NCT03522064
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.